Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ926MR)

This product GTTS-WQ926MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ926MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9159MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMGN-529
GTTS-WQ6289MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ13328MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ14950MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SHR-1210
GTTS-WQ5308MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ932MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ4048MR IVTScrip™ mRNA-Anti-IL36RN, BI 655130(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655130
GTTS-WQ7414MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA201
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW